Deepika Shah, MD
Ophthalmology · Chevy Chase, MDNPI 1316172489
Payments from drug & device makers
Across 487 payments — averaging $291.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$58K
- Sun Pharmaceutical Industries Inc.$45K
- Novartis$20K
- Biotissue Holdings Inc.$12K
- Kala Pharmaceuticals, Inc.$1K
- Alcon$594
- plus $5K from 19 others
What the payments were for
- Consulting fees$7,1856%
- Speaking & faculty fees$91,90075%
- Travel & lodging$10,9289%
- Food & beverage$12,46810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 117 | $57,978 |
| Sun Pharmaceutical Industries Inc. | 105 | $44,869 |
| Novartis | 68 | $20,355 |
| Biotissue Holdings Inc. | 25 | $12,409 |
| Kala Pharmaceuticals, Inc. | 12 | $1,168 |
| Alcon | 24 | $594 |
| Oyster Point Pharma, Inc. | 25 | $592 |
| Tarsus Pharmaceuticals, Inc. | 20 | $590 |
| Dompe US, Inc. | 10 | $528 |
| AbbVie(2 entities) | 12 | $378 |
| Harrow Eye, LLC | 17 | $365 |
| Shire North American Group Inc | 3 | $267 |
| Glaukos Corporation | 10 | $220 |
| Apellis Pharmaceuticals, Inc. | 2 | $217 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $186 |
| Sight Sciences, Inc. | 4 | $177 |
| Amgen | 8 | $177 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $160 |
| Eyepoint US, Inc. | 2 | $160 |
| NEW World Medical,inc. | 1 | $135 |
| Genentech USA, Inc. | 1 | $127 |
| Carl Zeiss Meditec, Inc. | 1 | $113 |
| Astellas Pharma US Inc | 1 | $111 |
| Eyevance Pharmaceuticals LLC | 2 | $42 |
| Rxsight Inc | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$54,695
- XIIDRA$44,432
- CEQUA$43,349
- Prokera$9,693
- EYSUVIS$960
- BLINK NUTRITEARS$700
- Oxervate$255
- AmnioGraft$148
- Kahook Dual Blade$135
- Clearpath$135
- Ahmed Glaucoma Valve$135
- Streamline$135
- SUSVIMO$127
- DEXYCU$124
- IC-8 Apthera IOL$123
- enVista MX60 IOL$123
- Syfovre$119
- CLARUS 500 Fundus Camera$113
- Izervay$111
- OMNI(R) SURGICAL SYSTEM (US)$104
How this compares
$141,950 in reported general payments places this provider in the 90th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 166 | $217,708 |
| XiidraLifitegrast | 60 | $87,448 |
| MieboPerfluorohexyloctane/Pf | 82 | $73,153 |
| CequaCyclosporine | 56 | $58,184 |
| Cyclosporine | 72 | $41,829 |
| TyrvayaVarenicline Tartrate | 27 | $26,107 |
| Loteprednol Etabonate | 45 | $8,177 |
| LumiganBimatoprost | 12 | $5,648 |
| LotemaxLoteprednol Etabonate | 18 | $5,542 |
| Travoprost | 19 | $3,348 |
| Brimonidine Tartrate | 19 | $2,918 |
| Prednisolone Acetate | 49 | $2,432 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $2,072 |
| Difluprednate | 13 | $1,437 |
| Latanoprost | 76 | $913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $378 | $223,356178 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $57,978 | $160,600142 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $44,869 | $58,18456 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $592 | $26,10727 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax | $186 | $13,71863 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Chevy Chase
- Thomas ClinchChevy Chase$449K
- Hylton MayerChevy Chase$145K
- Anand MantravadiChevy Chase$134K
- Kenneth SchorChevy Chase$85K
- Allen HuHagerstown$47.9M
- David WarrowHagerstown$10M
- Daniel FinkelsteinBaltimore$6.9M
- Eric SuanBaltimore$6.9M
- Peter CampochiaroBaltimore$5.4M
- Neil BresslerBaltimore$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.